» Articles » PMID: 32463730

Cognitive Profiles in Persons with Opioid Use Disorder Enrolled in Methadone Treatment

Overview
Specialties Neurology
Psychology
Date 2020 May 29
PMID 32463730
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Cognitive impairment is common in persons with opioid use disorder and associated with poor treatment outcomes, including elevated risk for relapse. Much less is known about the underlying structure of these deficits and the possible presence of cognitive phenotypes. A total of 177 adults (average 42.2 years of age, 52.0% male, 65.5% Caucasian) enrolled in a methadone maintenance treatment program completed the NIH Toolbox as part of a larger project. Cluster analyses revealed a 2-cluster solution-persons with intact cognitive function in all domains ( = 93; Intact) and those with impairments on tests of attention and executive function ( = 83; Impaired). Follow-up analyses revealed that the Impaired group was slightly older, more likely to self-identify as a racial/ethnic minority, and less likely to report consuming alcohol four or more times per week. These findings suggest the existence of distinct cognitive profiles in persons with opioid use disorder and encourage further examination, particularly studies to examine the possible benefits of routine screening for cognitive impairment as part of substance use treatment.

Citing Articles

Factors associated with cognitive flexibility in people with opioid-use disorder: a pilot study.

Regier P, Costa Macedo de Arruda T, Sinko L, Teitelman A, Childress A Front Psychiatry. 2025; 15():1505391.

PMID: 39748901 PMC: 11693614. DOI: 10.3389/fpsyt.2024.1505391.


Testing the feasibility, acceptability, and preliminary efficacy of integrating accommodation strategies into an HIV prevention intervention for people who inject drugs with cognitive dysfunction.

Mistler C, Shrestha R, Copenhaver M J Subst Use Addict Treat. 2024; 169:209582.

PMID: 39551147 PMC: 11769740. DOI: 10.1016/j.josat.2024.209582.


Neurocognitive performance of patients undergoing intravenous versus oral opioid agonist treatment: a prospective multicenter study on three-month treatment effects.

Chamakalayil S, Stohler R, Moldovanyi A, Gerber M, Brand S, Dursteler K Front Psychiatry. 2024; 15:1375895.

PMID: 39109370 PMC: 11300233. DOI: 10.3389/fpsyt.2024.1375895.


Social and cognitive determinants of medications for opioid use disorder outcomes: A systematic review using a social determinants of health framework.

Hernandez-Vallant A, Hurlocker M Appl Neuropsychol Adult. 2024; :1-25.

PMID: 38662711 PMC: 11502508. DOI: 10.1080/23279095.2024.2336195.


Application of the multiphase optimisation strategy (MOST) to optimise HIV prevention targeting people on medication for opioid use disorder (MOUD) who have cognitive dysfunction: protocol for a MOST study.

Mistler C, Shrestha R, Gunstad J, Collins L, Madden L, Huedo-Medina T BMJ Open. 2023; 13(6):e071688.

PMID: 37399447 PMC: 10314648. DOI: 10.1136/bmjopen-2023-071688.


References
1.
Copersino M, Fals-Stewart W, Fitzmaurice G, Schretlen D, Sokoloff J, Weiss R . Rapid cognitive screening of patients with substance use disorders. Exp Clin Psychopharmacol. 2009; 17(5):337-44. PMC: 3144764. DOI: 10.1037/a0017260. View

2.
Zahodne L, Nowinski C, Gershon R, Manly J . Depressive symptoms are more strongly related to executive functioning and episodic memory among African American compared with non-Hispanic White older adults. Arch Clin Neuropsychol. 2014; 29(7):663-9. PMC: 4263927. DOI: 10.1093/arclin/acu045. View

3.
Gallagher M, McLeod H, McMillan T . A systematic review of recommended modifications of CBT for people with cognitive impairments following brain injury. Neuropsychol Rehabil. 2016; 29(1):1-21. DOI: 10.1080/09602011.2016.1258367. View

4.
Lima F, Rabelo-da-Ponte F, Bucker J, Czepielewski L, Hasse-Sousa M, Telesca R . Identifying cognitive subgroups in bipolar disorder: A cluster analysis. J Affect Disord. 2018; 246:252-261. DOI: 10.1016/j.jad.2018.12.044. View

5.
Ersche K, Turton A, Chamberlain S, Muller U, Bullmore E, Robbins T . Cognitive dysfunction and anxious-impulsive personality traits are endophenotypes for drug dependence. Am J Psychiatry. 2012; 169(9):926-36. PMC: 3533378. DOI: 10.1176/appi.ajp.2012.11091421. View